Heron Therapeutics, Inc. (NASDAQ:HRTX) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On January8, 2018, Heron Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, certain of its financial results for the three and twelve months ended December31, 2017 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
This Item 2.02 and the Press Release attached hereto as Exhibit 99.1 are being furnished to the Securities and Exchange Commission.
Item 2.02 Regulation FD Disclosure.
Press Release.
On January8, 2018, the Company issued the Press Release providing, among other things, a general update on corporate progress, as described in the Press Release.
Corporate Presentation.
A copy of presentation materials describing the business of the Company, all or a part of which may be used by the Company in investor or scientific presentations from time to time, is furnished herewith as Exhibit 99.2 (the “Corporate Presentation”). The Corporate Presentation has also been posted on the Company’s website at www.herontx.com. The Company does not undertake any obligation to update the Corporate Presentation.
This Item 2.02, the Press Release and the Corporate Presentation are being furnished to the Securities and Exchange Commission.
Item 2.02 Financial Statements and Exhibits.
(d) Exhibits.
HERON THERAPEUTICS, INC. /DE/ ExhibitEX-99.1 2 d522181dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Heron Therapeutics Highlights Progress in CINV and Pain Management Franchises – SUSTOL® Fourth-Quarter 2017 Net Sales of Approximately $10 Million,…To view the full exhibit click here
About Heron Therapeutics, Inc. (NASDAQ:HRTX)
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company’s SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.